Drugs / Slulimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06415851 | Jun 2024 → May 2025 | colorectal cancer | Zhangfa Song | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Slulimab | “Slulimab is a humanized IgG4 monoclonal antibody with clear anti-tumor efficacy and easy management of adverse reactions.” NCT06415851 ↗ |
| Modality | Monoclonal antibody | “Slulimab is a humanized IgG4 monoclonal antibody with clear anti-tumor efficacy and easy management of adverse reactions.” NCT06415851 ↗ |
| Route | Intravenous | “Slulimab: 200 mg, intravenous infusion, day 1, q2w” NCT06415851 ↗ |